Login / Signup

Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse.

Laura E HoganPatrick A BrownLingyun JiXinxin XuMeenakshi DevidasTeena BhatlaMichael J BorowitzElizabeth A RaetzAndrew J CarrollNyla A HeeremaGerhard ZugmaierElad SharonMelanie Brooke BernhardtStephanie A TerezakisLia GoreJames A WhitlockStephen P HungerMignon L Loh
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
For children, adolescents, and young adults with B-ALL in LR first relapse, there was no statistically significant difference in DFS or OS between the blinatumomab and standard chemotherapy arms overall. However, blinatumomab significantly improved DFS and OS for the two thirds of patients with BM ± EM relapse, establishing a new standard of care for this population. By contrast, similar outcomes and poor DFS for both arms were observed in the one third of patients with IEM; new treatment approaches are needed for these patients (ClinicalTrials.gov identifier: NCT02101853).
Keyphrases